These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20233509)

  • 21. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
    Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(1):75-92. PubMed ID: 20014878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
    Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
    Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
    Vergnenegre A; Massuti B; de Marinis F; Carcereny E; Felip E; Do P; Sanchez JM; Paz-Arez L; Chouaid C; Rosell R;
    J Thorac Oncol; 2016 Jun; 11(6):801-7. PubMed ID: 26899757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
    Holmes J; Dunlop D; Hemmett L; Sharplin P; Bose U
    Pharmacoeconomics; 2004; 22(9):581-9. PubMed ID: 15209527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
    Borget I; Cadranel J; Pignon JP; Quoix E; Coudert B; Westeel V; Dansin E; Madelaine J; Madroszyk A; Friard S; Daniel C; Morin F; Chouaid C;
    Eur Respir J; 2012 Jan; 39(1):172-9. PubMed ID: 21659409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
    Dillon B; Naidoo B; Knight H; Clark P
    Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
    Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
    J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
    Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
    Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
    Popat S; Barbachano Y; Ashley S; Norton A; O'Brien M
    Lung Cancer; 2008 Feb; 59(2):227-31. PubMed ID: 17920156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
    Kawaguchi T; Ando M; Asami K; Okano Y; Fukuda M; Nakagawa H; Ibata H; Kozuki T; Endo T; Tamura A; Kamimura M; Sakamoto K; Yoshimi M; Soejima Y; Tomizawa Y; Isa S; Takada M; Saka H; Kubo A
    J Clin Oncol; 2014 Jun; 32(18):1902-8. PubMed ID: 24841974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
    Protsenko SA; Rudakova AV
    Vopr Onkol; 2015; 61(4):676-80. PubMed ID: 26571844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
    Chouaid C; Le Caer H; Locher C; Dujon C; Thomas P; Auliac JB; Monnet I; Vergnenegre A;
    BMC Cancer; 2012 Jul; 12():301. PubMed ID: 22817667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
    Horgan AM; Bradbury PA; Amir E; Ng R; Douillard JY; Kim ES; Shepherd FA; Leighl NB
    Ann Oncol; 2011 Aug; 22(8):1805-11. PubMed ID: 21273345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
    Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
    J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and economic review of erlotinib in non-small-cell lung cancer.
    Yeung K; Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):411-23. PubMed ID: 22971028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
    Lim EA; Lee H; Bae E; Lim J; Shin YK; Choi SE
    PLoS One; 2016; 11(8):e0160155. PubMed ID: 27483001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.
    Arellano J; Leteneux C
    J Med Econ; 2008; 11(2):363-66; author reply 366-70. PubMed ID: 19450092
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
    Chouaid C; Le Caer H; Corre R; Crequit J; Locher C; Falchero L; Dujon C; Berard H; Monnet I; Vergnenegre A
    Clin Lung Cancer; 2013 Mar; 14(2):103-7. PubMed ID: 22682669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.